Comparison of Body Size, Morphomics, and Kidney Function as Covariates of High‐Dose Methotrexate Clearance in Obese Adults with Primary Central Nervous System Lymphoma by Pai, Manjunath P. et al.
This is the author manuscript accepted for publication and has undergone full peer review but has 
not been through the copyediting, typesetting, pagination and proofreading process, which may 
lead to differences between this version and the Version of Record. Please cite this article as doi: 
10.1002/PHAR.2379
This article is protected by copyright. All rights reserved
DR AMIT  PAI (Orcid ID : 0000-0001-7119-5034)
Article type      : Original Research Article
Comparison of Body Size, Morphomics, and Kidney Function as Covariates of High-Dose 
Methotrexate Clearance in Obese Adults with Primary Central Nervous System 
Lymphoma 
Manjunath P. Pai1, Kenneth C. Debacker1, Brian Derstine2, June Sullivan2, Grace L. Su2,3 , 
Stewart C. Wang2
1Department of Clinical Pharmacy, College of Pharmacy, University of Michigan, Ann Arbor, MI 
48109
2Department of Surgery, Michigan Medicine, University of Michigan, Ann Arbor, MI 48109
3Department of Medicine, VA Ann Arbor Health System, Ann Arbor, Michigan, USA.
Key words: analytic morphomics, leucovorin, obesity, pharmacology, kidney function, body 
composition, pharmacokinetics
Running Title: Pharmacomorphomics of Methotrexate
Corresponding Author: 
Manjunath P. Pai
College of Pharmacy, University of Michigan
428 Church Street
Ann Arbor, MI 48109, USA
Email: amitpai@med.umich.edu
This article is protected by copyright. All rights reserved
ACKNOWLEDGEMENTS
We acknowledge the support of Sven Holcombe, Binu Enchakalody, and Nick Wang for 
writing the algorithm necessary to extract morphomic data from CT scans. This study was 
supported in part through start-up funds from the University of Michigan College of Pharmacy to 
M.P.P.
CONFLICTS
S.C.W. and J.A.S. are inventors of the Analytic Morphomics: High Speed Medical Image 
Automated Analysis Method (US patent 14/014,485). All other authors have no conflicts of 
interest to disclose regarding this work.
ABSTRACT 
Background: High-dose methotrexate (HD-MTX) is used to treat primary central nervous 
system lymphoma (PCNSL), but potential differences in MTX clearance (CL) due to obesity 
have not been studied. We characterized the relationship between HD-MTX CL and computed-
tomography (CT)-generated body composition (morphomic), body size descriptors, and 
laboratory measurements in a cohort of obese and non-obese patients with PCNSL.
Methods:  Medical records from adult patients with PCNSL treated with HD-MTX over a 10-
year period were queried. Individuals with CT data within 30 days of the first cycle of treatment 
were included. Population pharmacokinetic analysis was performed using a 2-compartment 
base structural model. We specifically compared body surface area (BSA) to standard body 
size, morphomic, and renal function estimation methods as covariates of HD-MTX CL.
Results:  The final data set consisted of non-obese (n=45) and obese (n=28) patients with 291 
observations (3 to 7 samples per patient) with a mean (standard deviation) weight of 69.8 (11.6) 
kg and 104 (14.9) kg, respectively (p= 0.0001). Vertebral body height was more informative than 
BSA of MTX CL. Similarly, a CL model incorporating age, albumin, and serum creatinine was 
more informative than kidney function equations and body size. The final model of MTX CL was 
based on age, albumin, serum creatinine, and vertebral body height.
Conclusions: Common clinical variables coupled with vertebral body height are more predictive 
of first cycle MTX CL than BSA, alternate body size descriptors, and commonly used kidney 
function equations.
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Primary central nervous system lymphoma (PCNSL) is a rare (4.4 cases per million 
persons annually) form of extranodal non-Hodgkin’s lymphoma that is limited to the brain, 
leptomeninges, spinal cord, and eyes.1 The median age at diagnosis is 65 years, and an 
increase in the incidence of this cancer has been noted over the past few decades.2-5 The 
prevailing therapy for newly diagnosed PCNSL is methotrexate (MTX), primarily a competitive 
inhibitor of dihydrofolate reductase that is responsible for folate activation in the thymine and 
purine biosynthetic pathway.6 Although MTX is a potent cytotoxic agent, poor blood-brain-barrier 
permeability necessitates administration of high-dose methotrexate (HD-MTX), typically 1 to 8 
g/m2 in combination with whole brain radiotherapy or other cytotoxic chemotherapy agents for 
treatment of PCNSL.1 Administration of HD-MTX to target brain cancer cells can negatively 
impact normal cells resulting in significant toxicities. The major acute toxicities associated with 
HD-MTX include nephrotoxicity, neurotoxicity, mucositis, myelosuppression, and hepatotoxicity.7 
High plasma concentrations between 24 and 48 hours from dosing have been linked with an 
increased risk for these toxicities.7 The elimination of MTX is primarily renal, and so hydration 
and urine alkalization are used to enhance MTX clearance (CL) and lower the risk of 
nephrotoxicity by reducing crystal formation in nephrons.7 Therapeutic drug monitoring (TDM) of 
MTX is also performed to provide a pharmacokinetic (PK)  guide for leucovorin rescue dosage.8-
10 Leucovorin or folinic acid is administered as an antidote to prevent death of normal cells by 
serving as the direct resource for the thymine and purine biosynthetic pathway. At present there 
is no consensus on the optimal dose of HD‐MTX or on the role of radiation in combination with 
MTX in the management of PCNSL.1
The rarity of PCNSL also limits our knowledge on the optimal dose of HD‐MTX in special 
populations, such as obesity.1 Although the association between obesity and PCNSL cancer 
survivorship is limited, data from breast, prostate, and colorectal cancer cohorts indicate poorer 
quality of life, a higher risk for cancer recurrence, and disease progression in obese patients.11 
To date, the literature on HD-MTX dosing in obesity is limited to a single case report in an obese 
(39.3 kg/m2) patient treated with MTX 8 to 10 g/m2 for osteosarcoma, leading to limited insights 
on potential differences in the PK of MTX across body size.12,13 Selection of body surface area 
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(BSA) as the metric for HD-MTX dosing is consistent with the traditional approach used with 
lowering the toxicity risk of most cytotoxic agents.14,15 However the relevance of this dosing 
strategy has not been carefully evaluated in obese patients.16 This is concerning given that 
more than a third of adult patients in the Unites States are obese.17 Routine use of TDM in 
patients receiving HD-MTX provides an opportunity to rectify this limitation. Current models also 
demonstrate that the toxicity profile of HD-MTX is predicted by the area under the curve (AUC) 
after the first cycle of therapy. As a consequence, optimal prediction of CL is likely to aid empiric 
dosage selection. Reliance solely on BSA to define the dosage of HD-MTX in theory may not be 
as useful as incorporation of other readily available clinical variables predictive of MTX CL.
Potential empiric dosing strategies of HD-MTX, instead of gram/m2 dosing, may include 
use of alternate body size descriptors, body composition measurements, or estimated kidney 
function values predictive of MTX CL. Two major alternate body size descriptors include 
adjusted body weight (adjBW) and lean body weight (LBW) that are also mathematical 
transformations of height and body weight but unlike BSA account for differences by sex.18 
Patients with PCNSL undergo multiple radiologic assessments that can also be used to 
characterize individual body composition. Our group has developed analytical morphomic tools 
that use existing radiologic data to generate estimates of skeletal muscle, fat, and other relevant 
body phenotype measures that can serve as scalars of PK parameters.19,20 Similar to body size, 
multiple equations exist to estimate kidney function that has traditionally included the Cockcroft-
Gault formula for creatinine clearance (eCrCL) and more recently the Chronic Kidney Disease 
Epidemiology (CKD-EPI) equation for the glomerular filtration rate (eGFR).21,22 The current 
investigation compared the PK of HD-MTX in obese and non-obese patients with PCNSL who 
had radiologic data for analytic morphomic assessment. Our objectives were to apply a semi-
mechanistic approach to comparison of body size, morphomic, and kidney function estimating 




This was a retrospective study conducted across the Michigan Medicine enterprise. Institutional 
review board approval was obtained from the University of Michigan prior to the collection of any 
patient data.
Design and Study Population
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Data were retrospectively obtained from “DATADIRECT”, a self-service clinical database 
developed and maintained by the University of Michigan. The query time frame was an 
approximately 10-year period between November 2007 and January 2018. Patient records were 
queried if the following criteria were satisfied: (i) patients greater than 18 years of age, (ii) 
diagnosis of PCNSL, (iii) therapy with intravenous MTX during the study period, (iv) 
measurement of MTX concentrations during the course of therapy, and (v) CT scan available 
within 30 days of the first measured MTX concentration. Data queried included patient 
demographics, encounters, MTX drug orders and administration times, and laboratory 
information. The clinical dataset was then matched to a radiologic database containing CT 
images to identify patients with data sufficient to generate analytic morphomic parameters. Data 
were password protected and stored on a secure platform maintained by the University. Data 
manipulation was accomplished using the R programming language and environment. Patients 
were excluded if they met any of the following criteria: (i) incomplete or missing MTX dosing 
information during the index course of therapy, (ii) lack of documentation of height and/or 
weight, (iii) CT imaging with an insufficient field of view to obtain morphomic measurements or 
image artifact impacting interpretation, and (iv) renal replacement therapy (including 
hemodialysis and continuous renal replacement therapy). 
Analytic Morphomics
Individual morphomic parameters were computed as previously described.23,24 In brief, a 
custom-built MATLAB-based (The Mathworks Inc., Natick, MA) algorithm was used to identify 
vertebral elements in a semiautomated manner from Digital Imaging and Communications in 
Medicine (DICOM) files of CT scans. These vertebral elements were then used to create an 
anatomic index. Consistent estimates of abdominal fat, skeletal muscle, and visceral cavity were 
obtained using measurements at the inferior aspects of the second (L2), third (L3), and fourth 
(L4) lumbar vertebral bodies. Volumetric estimates were made by multiplying measures of cross 
sectional area by the height of the corresponding vertebral body (L2, L3, and L4). In the case of 
fat volume this included the summation of subcutaneous and visceral fat volumes. Descriptions 
of specific morphomic measures are accessible through the Morphomics Data Dictionary 
(available at http://www.med.umich.edu/surgery/morphomics/data_dictionary).
Alternate Body Size and Kidney Function Estimates
Alternative body size scalars including ideal body weight (IBW), adjBW, LBW, and BSA using 
Mosteller’s adaptation were computed as previously described.18 In addition total body weight 
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(TBW) scaled as a power function [(TBW/average TBW)β] or as a fixed power function, 
allometrically as [(TBW/average TBW)0.75] were also tested. Estimates of renal function were 
calculated using the Cockcroft-Gault and CKD-EPI (eGFR_CKD-EPI).21,22 We also tested the 
four variable (age, sex, race, serum creatinine) and six variable (age, sex, race, serum 
creatinine, blood urea nitrogen, and albumin) Modification of Diet in Renal Disease (MDRD) 
formula referred to as MDRD4 and MDRD6, respectively.25,26 The modified Cockcroft-Gault 
(mCG) equation was used with each of the scalars of body weight listed above ([(140-age) × 
0.85 if female/serum creatinine]), with weight removed so that independent effects could be 
tested. 
Pharmacokinetic and Statistical Analyses
Pharmacokinetic analyses were performed using Pkanalix2019R2 (noncompartmental analysis), 
Monolix2019R2, and Sycomore2019R2 (Monolix Suite2019R2, Antony, France: Lixoft SAS, 
2019). For population PK analysis, the stochastic approximation expectation maximization 
(SAEM) algorithm was used within Monolix2019R2 and individual MTX dosing and 
concentration-time data. A 2-compartment, first order input and linear clearance parameterized 
model structure was selected given repeated documentation of this model for the intravenous 
MTX concentration-time profile in the literature. Given that initial parameter estimates can 
influence final parameter estimates, we also applied the nonparametric adaptive grid (NPAG) 
using the PMetrics® library implemented through R for comparison with the literature.27 We 
subsequently selected initial condition parameter estimates from a recent large study sample 2-
compartment model of HD-MTX.28 As expected, our objective was to test a large number of 
alternate body size (n=7), morphomic (n= 36), kidney function estimate (n= 4), and laboratory 
parameters (n= 6) required testing and so this analysis was performed in a stepwise manner 
given the large number of potential permutations, described as follows. Alternate models 
included incorporation of covariates with discrimination between models based on the Akaike 
Information Criterion (AIC) and Bayesian Information Criterion (BIC). These model comparisons 
were performed using Sycomore2019R2 within the Monolix suite. Visual predictive checks and 
nonparametric distribution error (NPDE) checks were performed with each model run through 
an efficient pipeline process within Monolix2019R2.
Series 1. We tested the base model (no-covariates), which was followed up with each body size 
parameter that included TBW, allometrically-scaled TBW ([(TBW/80 kg)0.75]), power-scaled TBW 
([(TBW/80 kg)β]), IBW, adjBW,  LBW. This was subsequently tested with each analytic 
morphomic parameter. Given the strong correlation between L2, L3, and L4 measurements 
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subsequent analyses were limited to the L3 measurements expected for the volume 
measurements that integrated all three lumbar measurements.
Series 2. We tested each kidney function estimating equation with no other covariates and then 
with individual body size and morphomic parameters added in a stepwise manner as covariates 
of CL. 
Series 3. We tested each laboratory parameter and demographic variable and identified the 
combination of age, albumin, and serum creatinine to be optimal (lowest AIC). Body size and 
morphomic parameters were then added in a stepwise manner as covariates of CL.
Given that the assay variability was not available to us, we relied on an additive and proportional 
error mode (COMBINED1 in Monolix) with initial conditions set to literature estimates. Patient 
demographics and morphomic measures were summarized using descriptive statistics stratified 
by the classification of obesity (Body Mass Index (BMI)≥ 30 kg/m2). Between group comparisons 
were accomplished using the Mann-Whitney U test and performed by sex for fair comparisons. 
Given that BSA serves as the dosing benchmark for MTX, the base model 1 was a 2-
compartment model with BSA as a covariate of CL. Since this base model (BSA only) was one 
of the least informative models, we selected BSA, age, albumin, and serum creatinine as 
covariates of CL to be the second referent model (base model 2). Statistical analyses were 




A total of 104 adult patients with PCNSL treated with HD-MTX were identified. The median [min, 
max] age, height, and weight of the population was 66 [26, 86] years, 168 [152.4, 198.1] cm, 
and 80.7 [46.5, 180] kg, respectively. There were 50 (18 obese) males and 54 (21 obese) 
females in the sample. The mean [min, max] MTX dose was 13.25 [2.27, 20.5] g and 6.97 [1.11, 
10.99] g/m2. Computed tomography data for all analytic morphomic parameters tested were 
available for 73 patients (70% of the study population) and the demographics, key laboratory 
variables, and MTX dosing details are included in Table 1. Similar to the overall PCNSL group, 
approximately 38.4% of the patients met the classification of obesity. The obese and non-obese 
groups were comparable with exception of expected differences by group for weight, BMI, and 
BSA. Kidney function estimates based on eGFR were not different between the two groups. 
Similarly, no significant difference was observed with eCrCL between groups when weight was 
excluded but not when TBW was included (expected bias of this equation). 
This article is protected by copyright. All rights reserved
Observed Concentration Profile
A total of 291 concentrations were measured in the 73 patients included in the analyses with a 
median [min, max] of 4 [3, 7] samples per patient. Figure 1 illustrates the superimposable 
central tendency profiles of MTX concentrations in non-obese and obese patients. The mean 
(standard deviation (SD)) AUC0-inf was 2150 (2056) hµM and 2582 (1625) hµM in the non-
obese and obese patients, respectively (p=0.349). The mean (SD) time to first and second 
concentration measurements were 18.8 (4.8) hours and 42.0 (5.3) hours, respectively. The 
median [interquartile range (IQR)] concentration at this first concentration benchmark was 14.0 
[7.98 – 34.7] µM and 19.6 [11.6 – 42.7] µM in the non-obese and obese groups, respectively 
(p=0.166). The median [IQR] concentration at this second concentration benchmark was 0.46 
[0.29 – 0.95] µM and 0.46 [0.30 – 0.88] µM in the non-obese and obese groups, respectively 
(p=0.923). The proportion of patients above 10 µM was 64% in the non-obese and 79% in the 
obese group at first measurement.  However, this difference was similar at the second 
measurement for concentrations above 0.5 µM, which was 46% in both the non-obese and 
obese groups. 
Body size and analytic morphomics
A summary of alternate body size descriptors andanalytic morphomics, are included in Table 2. 
Figure 2 provides an illustration of the CT scan cross plane translation into patient specific 
regions of subcutaneous fat, visceral fat, and skeletal muscle area. Analytic morphomic data 
from L3 is presented as it is representative and comparable to those of L2 and L4, and these 
parameters are combined to provide estimates of fat, skeletal muscle, and total body volume by 
group. All body size and body composition parameters were significantly different in obese 
compared non-obese groups by sex with exception to IBW, vertebral body height, and fascia to 
front skin (in males). 
Pharmacokinetic Analysis
The median parameter estimates through the NPAG analysis for CL, volume of the central 
compartment (V1), intercompartmental clearance (Q), and volume of the peripheral 
compartment (V2) were 8.30 L/h, 47.6 L, 0.091 L/h, and 3.47 L, respectively. These estimates 
closely matched the covariate unstructured model mean estimates of 10 L/h, 51.8 L, 0.103 L/h, 
and 4.5 L for CL, V1, Q, and V2, respectively, through SAEM. Table 3 provides a summary of the 
AIC values for the covariate unstructured model (None/None) along with the aforementioned 
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series-based permutations. When comparing body size descriptors alone, use of IBW (height-
based descriptor) had the lowest AIC and all other descriptors including BSA were less 
informative than a non-covariate structured model. Similarly, vertebral body height was the most 
informative analytic morphomic parameter. In relative terms, eCrCL using CG was more 
informative than eGFR equations but reliance on a CL model based on age, albumin, and 
serum creatinine (used to predict kidney function) resulted in the lowest reduction in AIC value. 
Vertebral body height further lowered this AIC value whereas all other body size and analytic 
morphomic variables increased the AIC. Table 4 includes a summary of two reference base 
models, where base model 1 represents current reliance on BSA to select doses, and base 
model 2 includes BSA, age, albumin, and serum creatinine. The final model incorporates 
vertebral body height and is associated with the lowest IIV for all four parameters. The following 
equation describes the final model for estimation of MTX CL:
Where, age is in years, Alb is albumin in g/dl, SCr is serum creatinine in mg/dl, VBH is vertebral 
body height in cm. Bootstrap analysis with 1000 bootstrap replicates to obtain 95% confidence 
intervals for all PK parameters are included in Table 4. Visual predictive check of the final model 
show that the 50th percentile and variability fall within 90% confidence bounds (Figure 3). This 
good overall performance of the final model provides reasonable internal validation for 
concentrations collected less than 96 hours from dosing and less so for concentration beyond 
this time point. Given the sparse data at these later time-points, focus on evaluation of a 2-
compartment structure, and limited clinical relevance for this extended time period, further 
optimization was not performed. The overall predictive performance is also noted in Figure 4 
through clear demonstration of symmetry in the individual weighted residual density and 
probability plots. Similarly, the NPDE  analysis showed adequate predictability with a majority of 
values within a normal distribution between -2 and 2.
DISCUSSION
Methotrexate has been in use as a cancer chemotherapy agent for the past 7 decades.  The 
similarity in the dose per unit surface area from mouse (0.018 kg), rat (0.25 kg), infant (8 kg), 
older child (20 kg), and adult (70 kg) compared to the dose per unit weight for 
methchlorethamine, MTX, 6-mercaptopurine, and actinomycin D serves as the basis for BSA-
dosing of several cancer chemotherapy agents today.15 However, unlike the stated generally 
accepted dose of 5 mg/day of MTX in adults treated in 1958, the dosage used today is 2000-
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fold higher (when considering PCNSL). In addition, upward shifts in the body weight distribution 
have changed the physique of patients treated with cancer over this time period.16 Methotrexate 
is a small polar molecule with greater than 80% of this agent excreted unchanged in urine or 
through the bile (8.7-26%) with very limited metabolism.29 Consistent with this physiochemical 
profile, distribution and clearance of this compound would not be expected to increase with 
adiposity and is not a component of current physiology-based PK models.30 In contrast, models 
of kidney function presently based on eCrCL and eGFR may be better predictors of MTX CL. 
On the other hand, the key clinical eCrCL equation includes TBW that can bias the estimate of 
kidney function in obese patients. To date, a thorough examination of the independent effects of 
body size, composition, and kidney function on HD-MTX PK has not been performed in adults 
and the current literature on MTX dosing in obesity is limited to a single case-report.12,13,16 In 
contrast, a thorough examination of the relationship between BMI and HD-MTX CL has been 
evaluated in children and determined to not be a relevant covariate.31 Clinicians have also used 
alternate dosing metrics in obese patients with cancer haphazardly, leading to issuance of 
guidance to curb this practice.32 Given this knowledge gap, we sought to sort out body size, 
composition, and kidney function effects on HD-MTX plasma PK. 
The richly sampled MTX concentration-time data used to inform leucovorin dose 
selection allowed us to evaluate the role of covariates on HD-MTX PK. The observed 
concentration-time data were almost superimposable in both groups stratified by the current 
definition of obesity. As clearly demonstrated by this thorough analysis, a base model without 
inclusion of BSA was better than inclusion of BSA. Methotrexate CL was best related to age, 
serum creatinine, and albumin, variables that are key components of eGFR and eCrCL 
estimation. In relative terms, body size and composition were less influential on the model of 
MTX CL. Although the final model included vertebral body height, this parameter may simply 
represent improved empiric kidney function estimation for this agent.33 
Vertebral body height has previously been shown to be correlate to kidney length.34-36 
Batson and Keats evaluated kidney size from 200 patients (56% male), 15 to 77 years of age, 
75% between 20 to 60 years of age. Interestingly, 97.3% of the 400 measurements were within 
the range of L1 to L4 measurements and were independent of age and sex.32 Kidney size 
correlates with kidney function but there are no published nomograms to provide comparative 
data to benchmark kidney size in this manner.36 Our finding of this correlation between CL and 
vertebral body height suggests that characterization of kidney size could be an informative 
parameter. Although kidney size was not directly measured through analytic morphomics in this 
instance, such an evaluation is plausible with this technology in the future. These findings are in 
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line with several population PK studies that document the close relationship between HD-MTX 
CL and kidney function.28,37-40
A population PK study in children and adults treated with HD-MTX for PCNSL revealed 
typical values of V1, CL, Q, and V2 were 24.5 L, 6.67 L/h, 0.047 L/h, and 1.32 L, respectively; 
much lower than the values observed in our study. 37 These values match several studies that 
have been performed in Asian patients with smaller body habitus.40-42 In contrast, a study in  
European patients reported base model estimates for V1, CL, Q, and V2 as 34.0 L, 10.8 L/h, 
0.35 L/h, and 6.3 L, respectively, which more closely match estimates from the present study.38  
In their model only CrCL and BSA served as covariates of CL and no other body size or 
laboratory values were predictive of other PK parameters.38 Similarly in the most comprehensive 
population PK model to date, base model estimates for V1, CL, Q, and V2 as 52.1 L, 12 L/h, 0.13 
L/h, and 5.6 L, respectively, where CL was parameterized as a function of eGFR and 
allometrically scaled to TBW.28  In the present study, we show that allometrically scaling TBW is 
not more informative than other body size descriptors. Also, none of these prior studies have 
evaluated the potential influence of morphomic and alternate body size descriptors as 
covariates of MTX PK that were also not informative overall. 
The influence of body composition on the pharmacokinetics of cancer chemotherapy has 
recently been reviewed.16 This analysis reveals that cross-sectional imaging, as used in the 
current study, provides reliable estimates of body composition in oncology patients. However, 
the vast majority of studies to date have focused on the association between body composition 
and the risk of chemotherapy toxicity.16 In these studies, patients with lower lean mass 
(computed based on muscle area) have higher observed drug concentrations and experience a 
higher incidence of adverse events. These differences have been presumed to be a result of 
altered volume of distribution and CL. In the present study, we included individuals with a 
median [min, max] skeletal muscle area at L3 of 123 [66.5, 212] cm2 that match the range 
observed in a previous study used to estimate lean mass.43 However, we were not able to 
demonstrate a meaningful relationship between these body composition metrics and MTX PK 
parameters. Our findings are consistent with recent evaluation of skeletal muscle and 5-
fluorouracil PK in patients with colorectal cancer.44 No differences in fluorouracil AUC were 
observed in patients with low skeletal muscle area compared to patients with normal skeletal 
muscle for age.
Our study has limitations inherent to its retrospective design. Exclusion of patients 
without CT data was unlikely to have influenced our findings given that the exposure profiles 
among obese and non-obese patients were almost superimposable. Our analyses were also 
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limited to the first cycle of therapy; previous studies have demonstrated changes in PK of MTX 
between cycles.37-42 We chose to limit our analysis to the first cycle to reduce the potential 
influence of MTX use itself on body composition and CL that could cloud our interpretation of 
these relationships. Furthermore, these metrics are likely to be less relevant once TDM is 
performed after the first cycle given that individual PK parameter estimates can inform dose 
management in subsequent cycles.38  We also did not evaluate time-varying models of MTX CL 
due to alterations in kidney function or incorporate the influence of urinary alkalization as this 
information was missing. Despite these limitations, our study is the first to disambiguate the 
relationship between HD-MTX PK, body size, composition, and kidney function in adult patients 
with PCNSL. Demonstration that obesity has limited influence on MTX PK implies that altered 
dosing schemas are unlikely in this population. Dosing MTX based on BSA is simple but 
expected to be less precise than factoring age, albumin, and serum creatinine for this agent. 
CONCLUSION
The plasma PK of HD-MTX are comparable in obese and non-obese adult patients with PCNSL. 
Body size does not account for interindividual variability in HD-MTX PK, whereas variables 
associated with kidney function estimation and vertebral body height are predictive of clearance.
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Table 1. Demographic Variables among Obese and Non-Obese Patients with Morphomic Data
Variable Non-Obese (n=45) Obese (n=28) p-value
Mean (SD) Mean (SD)
Age (Years) 64.1 (11.3) 64.9 (11.7) 0.793
Height (cm) 170 (8.9) 169 (10.7) 0.642
Total Body Weight (kg) 69.8 (11.6) 104 (14.9) <0.001
BMI (kg/m2) 24.0 (3.0) 36.5 (6.0) <0.001
BSA (m2) 1.81 (0.19) 2.20 (0.19) <0.001
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Serum Creatinine (mg/dl) 0.80 (0.29) 0.82 (0.24) 0.774
BUN (mg/dl) 18.9 (8.1) 18.0 (9.8) 0.664
Albumin (mg/dl) 3.5 (0.4) 3.6 (0.4) 0.179
Hematocrit (%) 32.9 (4.3) 31.7 (5.1) 0.736
Methotrexate Dose (g/m2) 6.94 (1.91) 6.60 (1.89) 0.458
Methotrexate Dose (g) 12.5 (3.70) 14.5 (4.46) 0.040
eCrCL_TBW (ml/min) 96.5 (44.5) 134 (56.5) 0.003
eCrCL_No Weight (ml/min) 95.3 (34.1) 94.5 (37.6) 0.816
eGFR_CKD-EPI (ml/min/1.73 m2) 86.5 (21.8) 87.7 (21.2) 0.735
eGFR_MDRD4 (ml/min/1.73 m2) 97.7 (43.8) 89.5 (29.1) 0.379
eGFR_MDRD6 (ml/min/1.73 m2) 93.9 (41.7) 89.3 (29.7) 0.619
SD, standard deviation; BMI, body mass index; BSA, body surface area; BUN, blood urea 
nitrogen; eCrCL, estimated creatinine clearance using Cockcroft-Gault equation with TBW or no 
weight; TBW, total body weight; eGFR, estimate glomerular filtration rate; CKD-EPI, chronic 
kidney disease epidemiology equation; MDRD4, 4-variable modification of diet in renal disease 
equation; MDRD6, 6-variable modification of diet in renal disease equation,
Table 2. Comparison of body size descriptors and analytic morphomic variables in non-obese 











Ideal Body Weight (kg) 56.1 (5.8) 55.3 (7.4) 72.4 (5.1) 71.2 (8.7)
Adjusted Body Weight (kg) 59.2 (6.0) 73.8 (9.1)a 74.1 (6.3) 85.4 (8.1)a
Lean Body Weight (kg) 40.5 (4.1) 51.7 (5.6) a 59.2 (5.7) 69.9 (6.4)a
Analytic Morphomic-L3
Vertebral body height (cm) 3.22 (0.32) 3.06 (0.37) 3.27 (0.31) 3.37 (0.27)
Vertebral body to front skin 
(cm)
10.2 (2.5) 15.0 (3.0)a 12.8 (3.30) 15.7 (3.08)a
Fascia to front skin (cm) 2.42 (0.93) 3.65 (0.93)a 2.19 (0.56) 2.29 (0.93)
Vertebral body to fascia (cm) 7.88 (2.30) 11.4 (2.92)a 10.5 (3.32) 13.3 (3.73)a
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Spine to back skin (cm) 2.38 (1.13) 4.93 (1.67)a 2.12 (1.19) 3.97 (1.43)a
Body depth (cm) 21.9 (3.1) 29.1 (4.0)a 24.9 (3.40) 29.9 (3.43)a
Visceral cavity area (cm2) 361 (68.3) 538 (125)a 523 (122) 673 (154)a
Subcutaneous area (cm2) 202 (89.0) 416 (146)a 201 (76.6) 318 (85.4)a
Subcutaneous fat area (cm2) 179 (91.0) 384 (136)a 173 (72.0) 284 (83.0)a
Visceral fat area (cm2) 95.7 (62.7) 228 (96.5)a 173 (104) 303 (121)a
Skeletal muscle area (cm2) 95.8 (14.2) 125 (24.9)a 141 (27.4) 167 (26.7)a
Total body area (cm2) 563 (131) 955 (241)a 724 (175) 991 (165)a
Analytic Morphomic-L2, L3, and L4 
combined
Fat volume (cm3) 2502 (1312) 5468 (2047)a 3382 (1886) 5804 (1476)a
Skeletal muscle volume (cm3) 862 (169) 1107 (247)a 1343 (335) 1599 (289)a
Total body volume (cm3) 6741 (1872) 11511 (3355) a 10070 (3498) 14341(3072)a
ap<0.05, comparing obese to non-obese within sex
Table 3. Summary of the Akaike information criterion for each of the tested body size and 
morphomic model combinations without kidney function (“None”), with kidney function 
equations, and demographic/laboratory model based on age, albumin (Alb), and serum 
creatinine (SCr) .
Variables None CKD-EPI MDRD4 MDRD6 CG
Age, 
Alb, SCr
None 188.46 182.80 186.19 182.51 180.30 162.90
Body Weight Descriptors
Body surface area 192.25 178.52 190.74 194.85 187.77 170.16
Total Body Weight 195.61 180.24 191.20 186.00 182.72 169.80
Total Body Weightβ 189.16 181.65 190.97 193.57 181.34 170.69
Total Body Weight0.75 194.58 181.44 186.83 187.78 182.81 167.12
Ideal Body Weight 187.30 184.57 191.23 185.50 182.65 166.01
Adjusted Body Weight 189.80 185.08 189.65 188.66 182.22 166.46
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Lean Body Weight 190.58 182.09 194.09 186.95 182.03 170.45
Analytic Morphomic-L3
Vertebral body height 185.74 179.46 187.04 186.59 175.00 162.31
Vertebral body to front skin 190.24 182.14 191.66 189.28 184.57 166.68
Fascia to front skin 190.92 179.21 190.72 191.22 179.34 166.10
Vertebral body to fascia 190.63 182.60 186.78 187.59 180.51 169.31
Spine to back skin 192.57 180.65 189.17 185.51 182.92 163.89
Body depth 189.07 179.31 188.28 182.85 179.32 165.57
Visceral cavity area 196.09 181.61 188.40 184.27 180.04 169.96
Subcutaneous area 189.59 184.51 190.43 185.79 181.92 163.56
Subcutaneous fat area 193.04 184.46 189.54 185.13 182.66 164.08
Visceral fat area 188.15 183.87 188.68 188.58 181.17 169.39
Skeletal muscle area 187.76 182.70 189.86 184.69 184.45 166.86
Total body area 193.97 177.35 190.47 185.23 183.31 165.36
Analytic Morphomic-L2, L3, and L4 combined
Fat volume 196.50 182.70 185.77 189.16 184.04 165.92
Skeletal muscle volume 187.83 184.31 189.29 189.11 179.28 167.72
Total body volume 189.21 180.11 186.62 185.12 184.54 166.86
CKD-EPI, chronic kidney disease epidemiology equation; MDRD4, 4-variable modification of 
diet in renal disease equation; MDRD6, 6-variable modification of diet in renal disease equation, 
CG, Cockcroft-Gault equation without weight




Base  Model Final Model Bootstrap of Final Model
1 2 Estimate 95% CI
AIC 192.25 170.16 162.31
CL (L/h) 8.67 11.1 6.87 7.58 3.16 – 14.31
V1 (L/h) 50.4 45.6 42.4 46.22 39.10 – 53.75
Q (L/h) 0.097 0.092 0.0825 0.0919 0.0693 – 0.117
V2 (L/h) 4.10 3.25 2.88 3.54 2.47 – 4.76
Covariate effect on CL
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  BSA 0.126 -0.094
  Albumin 0.689 0.642 0.662 0.280 –1.057
  Serum creatinine -0.234 -0.234 -0.244 -0.416 – -0.092
  Age -0.539 -0.508 -0.524 -0.795 – -0.271
  Vertebral body height 0.322 0.393 0.0238 – 0.773
IIV (%)
CL 21 16 16 16 12 – 19
V1 12 14 11 9.6 5.1 – 16
Q 54 49 48 54 39 – 67
V2 54 59 55 55 42-67
Residual Variability
Additive 0.0012 0.0023 0.0013 0.0020 0.000095 – 
0.0060
Proportional 0.25 0.24 0.24 0.22 0.18 – 0.26
Abbreviations: CI, confidence interval; AIC, Akaike information criterion; V1, volume of the 
central compartment; CL, clearance; Q, intercompartmental clearance; V2, volume of the 
peripheral compartment; BSA, body surface area; IIV, interindividual variability.
Figure 1. Observed (scatter) methotrexate concentrations and fractional polynomial fit 
(predicted) plot in non-obese and obese patients
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Figure 2. Illustrative example of patient-specific computed tomography imaging translation by 
analytic morphomics into subcutaneous fat area (A), visceral fat area (B), and skeletal muscle 
area (C)
Figure 3. Prediction corrected visual predictive check plot of the final model on a log10 scale 
showing the observed data (scatter data) against the 10th, 50th, and 90th percentile line plots of 
the observed data against the 90% confidence intervals (pink and blue shade smoothed by 
linear interpolation) for the model-simulated data.
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Figure 4. Goodness of fit plots of the final model represented by the density and probability 
plots of the conditional distribution of the individual weighted residuals (IWRES) and the 
nonparametric distributional error (NPDE)
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